Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07266428 · ClinicalTrials.gov registry record · Phase 1

A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by Ottimo Pharma Limited.

Recruiting
Registry status
Phase 1
Development phase
170
Enrollment target
4
Study locations

NCT07266428 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Ottimo Pharma Limited. The registered enrollment target is 170 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (14% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07266428, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Ottimo Pharma Limited.

RECRUITING
Registry status
Phase 1
Development phase
170 participants
Enrollment target
4
Study locations

Study Summary

The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects that it may cause. The trial will also see if OTP-01 causes tumors to shrink and how the body processes OTP-01 by measuring drug levels in the blood. The main questions this study aims to answer are: * What is the recommended dose of OTP-01 for adults with solid tumors? * Is OTP-01 safe and tolerable? * Does OTP-01 reduce tumor growth? Participants will: * Receive OTP-01 through an infusion into a vein. Doses will be spaced out and never more than once a week. * Have blood tests to evaluate safety and drug levels of OTP-01. These will be done often at first and then less frequently as treatment continues. * Have radiographic scans of their tumor at baseline and during the study at regular intervals. * Have the choice to have an optional tumor biopsy before and after treatment to help researchers understand how OTP-01 affects cancer and the immune system. These biopsies are voluntary and will not affect participation in the study.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG OTP-01

Study Locations (4)

Michigan

  • South Texas Accelerated Research Therapeutics (START) Midwest - Grand Rapids

Texas

  • South Texas Accelerated Research Therapeutics (START) - San Antonio

Utah

  • START Mountain Region - West Valley City

Other

  • Linear Clinical Research - Nedlands

Trial Details

FieldValue
Enrollment Target 170 participants
Start Date 2025-12-17
Est. Completion 2028-12
Phase Phase 1

Sponsor

Ottimo Pharma Limited

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07266428

The ClinicalTrials.gov registry entry for NCT07266428 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (14% lower). The listed sponsor is Ottimo Pharma Limited, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which OTP-01 is the first listed.

NCT07266428 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Michigan, Texas, Utah.

Frequently Asked Questions

What is clinical trial NCT07266428 about?

NCT07266428 is a clinical study titled "A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors". The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects that it may cause. The trial will also see if OTP-01 causes tumors to shrink and how the body processes...

What is the current status of trial NCT07266428?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 170 participants. The study started on 2025-12-17. Estimated completion is 2028-12.

What conditions does trial NCT07266428 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT07266428?

The interventions under investigation include: OTP-01 (DRUG).

Who is sponsoring clinical trial NCT07266428?

This trial is sponsored by Ottimo Pharma Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07266428 being conducted?

This trial has 4 study locations across Michigan, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.